Literature DB >> 21106941

Adducin- and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin, part 2: clinical studies.

Chiara Lanzani1, Lorena Citterio, Nicola Glorioso, Paolo Manunta, Grazia Tripodi, Erika Salvi, Simona Delli Carpini, Mara Ferrandi, Elisabetta Messaggio, Jan A Staessen, Daniele Cusi, Fabio Macciardi, Giuseppe Argiolas, Giovanni Valentini, Patrizia Ferrari, Giuseppe Bianchi.   

Abstract

Twenty years of genetic studies have not contributed to improvement in the clinical management of primary arterial hypertension. Genetic heterogeneity, epistatic-environmental-biological interactions, and the pathophysiological complexity of hypertension have hampered the clinical application of genetic findings. In the companion article, we furnished data from rodents and human cells demonstrating two hypertension-triggering mechanisms--variants of adducin and elevated concentrations of endogenous ouabain (within a particular range)--and their selective inhibition by the drug rostafuroxin. Here, we have investigated the relationship between variants of genes encoding enzymes for ouabain synthesis [LSS (lanosterol synthase) and HSD3B1 (hydroxy-δ-5-steroid dehydrogenase, 3β- and steroid δ-isomerase 1)], ouabain transport {MDR1/ABCB1 [ATP-binding cassette, sub-family B (MDR/TAP), member 1]}, and adducin activity [ADD1 (adducin 1) and ADD3], and the responses to antihypertensive medications. We determined the presence of these variants in newly recruited, never-treated patients. The genetic profile defined by these variants predicted the antihypertensive effect of rostafuroxin (a mean placebo-corrected systolic blood pressure fall of 14 millimeters of mercury) but not that of losartan or hydrochlorothiazide. The magnitude of the rostafuroxin antihypertensive effect was twice that of antihypertensive drugs recently tested in phase 2 clinical trials. One-quarter of patients with primary hypertension display these variants of adducin or concentrations of endogenous ouabain and would be expected to respond to therapy with rostafuroxin. Because the mechanisms that are inhibited by rostafuroxin also underlie hypertension-related organ damage, this drug may also reduce the cardiovascular risk in these patients beyond that expected by the reduction in systolic blood pressure alone.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21106941     DOI: 10.1126/scitranslmed.3001814

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  30 in total

Review 1.  Endogenous cardiotonic steroids in kidney failure: a review and an hypothesis.

Authors:  John M Hamlyn; Paolo Manunta
Journal:  Adv Chronic Kidney Dis       Date:  2015-05       Impact factor: 3.620

Review 2.  Personalized Therapy of Hypertension: the Past and the Future.

Authors:  Paolo Manunta; Mara Ferrandi; Daniele Cusi; Patrizia Ferrari; Jan Staessen; Giuseppe Bianchi
Journal:  Curr Hypertens Rep       Date:  2016-03       Impact factor: 5.369

Review 3.  How does pressure overload cause cardiac hypertrophy and dysfunction? High-ouabain affinity cardiac Na+ pumps are crucial.

Authors:  Mordecai P Blaustein
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-07-21       Impact factor: 4.733

Review 4.  The emerging role for rat models in gene discovery.

Authors:  Melinda R Dwinell; Jozef Lazar; Aron M Geurts
Journal:  Mamm Genome       Date:  2011-07-06       Impact factor: 2.957

Review 5.  Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation.

Authors:  Frank S Ong; Joshua L Deignan; Jane Z Kuo; Kenneth E Bernstein; Jerome I Rotter; Wayne W Grody; Kingshuk Das
Journal:  Pharmacogenomics       Date:  2012-03       Impact factor: 2.533

Review 6.  How NaCl raises blood pressure: a new paradigm for the pathogenesis of salt-dependent hypertension.

Authors:  Mordecai P Blaustein; Frans H H Leenen; Ling Chen; Vera A Golovina; John M Hamlyn; Thomas L Pallone; James W Van Huysse; Jin Zhang; W Gil Wier
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-11-04       Impact factor: 4.733

Review 7.  The pump, the exchanger, and the holy spirit: origins and 40-year evolution of ideas about the ouabain-Na+ pump endocrine system.

Authors:  Mordecai P Blaustein
Journal:  Am J Physiol Cell Physiol       Date:  2017-11-07       Impact factor: 4.249

Review 8.  Endogenous Ouabain: Recent Advances and Controversies.

Authors:  John M Hamlyn; Mordecai P Blaustein
Journal:  Hypertension       Date:  2016-07-25       Impact factor: 10.190

9.  Preoperative endogenous ouabain predicts acute kidney injury in cardiac surgery patients.

Authors:  Elena Bignami; Nunzia Casamassima; Elena Frati; Chiara Lanzani; Laura Corno; Ottavio Alfieri; Stephen Gottlieb; Marco Simonini; Keyur B Shah; Anna Mizzi; Elisabetta Messaggio; Alberto Zangrillo; Mara Ferrandi; Patrizia Ferrari; Giuseppe Bianchi; John M Hamlyn; Paolo Manunta
Journal:  Crit Care Med       Date:  2013-03       Impact factor: 7.598

Review 10.  Salt Sensitivity: Challenging and Controversial Phenotype of Primary Hypertension.

Authors:  Rossella Iatrino; Paolo Manunta; Laura Zagato
Journal:  Curr Hypertens Rep       Date:  2016-09       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.